Rapid Drug Detox can help detox you from NUCYNTA® (Tapentadol).
This is a new schedule II narcotic, similar to other opiates. NUCYNTA® was approved just recently by the FDA for pain therapy for the relief of moderate to severe acute pain in patients 18 years of age or older.
NUCYNTA® has been described as ‘tramadol on steroids’. It was developed by Grunenthal a German company, the same company that invented tramadol. It seems to have a similar make-up tramadol with the dual opioid/non-opioid effect. NUCYNTA® is available in 50 mg, 75 mg, and 100 mg strengths and seems to be closely related to Tramadol/Ultram.
The development of a potentially life-threatening serotonin syndrome may occur with use of SNRI products including NUCYNTA® particularly with concomitant use of serotonergic drugs such as SSRIs, SNRIs, TCAs, MAOIs and triptans, and with drugs which impair metabolism of serotonin (including MAOIs). Serotonin syndrome may include mental-status changes (e.g., agitation, hallucinations and coma), autonomic instability (e.g., tachycardia, labile blood pressure and hyperthermia), neuromuscular aberrations (e.g., hyperreflexi and incoordination) and/or gastrointestinal symptoms (e.g. nausea, vomiting, and diarrhea).
Withdrawal symptoms may occur if NUCYNTA® is discontinued abruptly. These symptoms may include: anxiety, sweating, insomnia, rigors, pain, nausea, tremors, diarrhea, upper respiratory symptoms, piloerection, and rarely, hallucinations.
TAPENTADOL TARGETS BOTH ASCENDING AND DESCENDING PATHWAYS IN ONE CENTRALLY ACTING ORAL ANALGESIC
Combines 2 analgesic mechanisms
- Mu-opioid agonist*
- Norepinephrine reuptake inhibitor (NRI)*
In the near future RDD Center will no doubt hear from patients addicted to this drug and find it difficult to withdraw. We will offer an anesthesia detoxification treatment to patients unable to stop this drug and will reduce extreme withdrawal symptoms.